Abstract
Bone scintigraphy provides functional or metabolic information to complement the structural information provided by radiographic techniques. The radiopharmaceuticals employed are administered intravenously, delivered to the surface of bone by the blood, and bind to newly formed bone. About one-half of the administered radiopharmaceutical localises in the skeleton while the remainder is cleared rapidly via the kidneys. Thus, scintigraphy is performed 1–3 h after injection, when an adequate target to background ratio has been achieved. The main tracers used are 99mTc-bisphosphonates (MDP, HDP) for SPECT and 18F-fluoride for PET. New tracers are under development but it remains to be seen whether they will offer significant clinical advantage over the current well-established agents.
Keywords
- Positron Emission Tomography
- Bone Scintigraphy
- Blood Clearance
- Positron Emission Tomography Tracer
- Amorphous Calcium Phosphate
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
ARSAC (Administration of Radioactive Substances Advisory Committee) (2006) Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Health Protection Agency, Chilton
Bauer GC, Carlsson A, Lindquist B (1957) Metabolism of Ba140 in man. Acta Orthop Scand 26:241–254
Blake GM, Park-Holohan SJ, Cook GJ et al (2001) Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 31:28–49
Blau M, Nagler W, Bender MA (1962) Fluorine-18: a new isotope for bone scanning. J Nucl Med 3:332–334
Charkes ND, Sklaroff DM, Bierly J (1964) Detection of metastatic cancer to bone by scintiscanning with strontium 87m. Am J Roentgenol Radium Ther Nucl Med 91:1121–1127
Cheng KT, Shaw SM, Pinkerton TC et al (1985) A Walker 256 tumor-induced osteogenic small animal model for the evaluation of [99mTc] diphosphonate radiopharmaceuticals. Int J Nucl Med Biol 12:197–208
El-Mabhouh AA, Mercer JR (2008) 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases. Eur J Nucl Med Mol Imaging 35:1240–1248
Fleisch H, Russell RG, Francis MD (1969) Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165:1262–1264
Fleming WH, McIlraith JD, King ER (1961) Photoscanning of bone lesions utilizing strontium 85. Radiology 77:635–636
Garnuszek P, Pawlak D, Licińska I et al (2003) Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals. Appl Radiat Isot 58:481–488
Goeckeler WF, Edwards B, Volkert WA et al (1987) Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 28:495–504
Grant FD, Fahey FH, Packard AB et al (2008) Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 49:68–78
Handeland A, Winderen Lindegaard M, Heggli D-E (1989) Biodistribution of anionic separated MDP complexes from different MDP preparations. Eur J Nucl Med 15:609–611
Hawkins RA, Choi Y, Huang S-C et al (1992) Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 33:633–642
Hockley PG, Scott PJH (2010) An automated method for preparation of [18F]sodium fluoride for injection, USP to address the technetium-99m isotope shortage. Appl Radiat Isot 68:117–119
Jurisson SS, Benedict JJ, Elder RC et al (1983) Calcium affinity of coordinated diphosphonate ligands. Single-crystal structure of [(en)2Co(O2P(OH)CH2P(OH)O2)]ClO4·H2O. Implications for the chemistry of technetium-99m-diphosphonate skeletal imaging agents. Inorg Chem 22:1332–1338
Lin JH (1996) Biosphosphonates: a review of their pharmacokinetic properties. Bone 18:75–85
Merrick MV (1975) Bone scanning. Br J Radiol 48:307–351
Mitterhauser M, Toegel S, Wadsak W et al (2007) Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nucl Med Biol 34:391–397
Moore AE, Blake GM, Fogelman I (2007) A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentration. Nucl Med Commun 28:187–192
Moore AE, Blake GM, Fogelman I (2008) Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling. J Nucl Med 49:375–382
Ogawa K (2008) Radiopharmaceuticals for bone metastasis imaging. In: Pillai MRA (ed) Technetium radiopharmaceuticals: status and prospective. International Atomic Energy Agency, Vienna
Ogawa K, Mukai T, Inoue Y et al (2006) Development of a novel 99mTc-chelate – conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med 47:2042–2047
Perez R, Cohen Y, Henry R et al (1972) A new radiopharmaceutical for 99mTc bone scanning. J Nucl Med 13:788–789
Ram PC, Fordham EW (1979) A historical survey of bone scanning. Semin Nucl Med 9:190–196
Shani J, Amir D, Soskolne WA et al (1990) Correlations between uptake of technetium, calcium, phosphate, and mineralization in rat tibial bone repair. J Nucl Med 31:2011–2014
Spencer RP, Lange RC, Treves S (1971) Use of 135mBa and 131Ba as bone-scanning agents. J Nucl Med 12:216–221
Subramanian G, McAfee JG (1971) A new complex of 99mTc for skeletal imaging. Radiology 98:192–196
Subramanian G, McAfee JG, Bell EG et al (1972a) 99mTc-labeled polyphosphate as a skeletal imaging agent. Radiology 102:701–704
Subramanian G, McAfee JG, Blair RJ et al (1972b) 99mTc-EHDP: potential radiopharmaceutical for skeletal imaging. J Nucl Med 13:947–950
Subramanian G, McAfee JG, Blair RJ et al (1975a) Technetium-99m-methylene diphosphonate – a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 16:744–755
Subramanian G, McAfee JG, Blair RJ et al (1975b) Technetium-99m-labeled stannous imidodiphosphate, a new radiodiagnostic agent for bone scanning: comparison with other 99mTc complexes. J Nucl Med 16:1137–1143
Toegel S, Hoffmann O, Wadsak W et al (2006) Uptake of bone-seekers is solely associated with mineralization! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride. Eur J Nucl Med Mol Imaging 33:491–494
Torres Martin de Rosales R, Finucane C et al (2009) Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases. Chem Commun 2009:4847–4849
van Langevelde A, Driessen OMJ, Pauwels EKJ et al (1977) Aspects of 99mTechnetium binding from an ethane-l-hydroxy-l, l-diphosphonate-99mTc complex to bone. Eur J Nucl Med 2:47–53
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ballinger, J.R. (2012). Bone Scintigraphy: SPECT and PET Tracers. In: Fogelman, I., Gnanasegaran, G., van der Wall, H. (eds) Radionuclide and Hybrid Bone Imaging. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-02400-9_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-02400-9_14
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-02399-6
Online ISBN: 978-3-642-02400-9
eBook Packages: MedicineMedicine (R0)